-
Sector Analysis
Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Non Alcoholic Fatty Liver Pipeline Drugs Analysis Overview Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease characterized by hepatic steatosis when no other causes for secondary hepatic fat accumulation (such as excessive alcohol consumption) can be identified. NAFLD ranges from the more benign condition of non-alcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which is at the more severe end of the spectrum. The NAFLD marketed and pipeline drugs market research report provides a data-driven overview of the...